×

The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC). Lee JY, Lim SH, Lee MY, Kim HS, Ahn JS, Im YH, Park YH. PLoS One. 2016 Feb 22;11(2):e0149432.

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ. Oncotarget. 2016 Jan 9.

Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Lee JY, Sun JM, Oh DR, Lim SH, Goo J, Lee SH, Kim SB, Park KU, Kim HK, Hong DS, Kim JS, Kim SG, Yi SY, Yun HJ, Hyun MS, Kim HJ, Jung SH, Park K, Ahn YC, Ahn MJ. Radiother Oncol. 2015 Dec 16

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Lee JY, Sun JM, Lim SH, Kim HS, Yoo KH, Jung KS, Song HN, Ku BM, Koh J, Bae YH, Lee SH, Ahn JS, Park K, Ahn MJ. Clin Cancer Res. 2015 Dec 14

Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Lee JY, Park K, Lim SH, Kim HS, Yoo KH, Jung KS, Song HN, Hong M, Do IG, Ahn T, Lee SK, Bae SY, Kim SW, Lee JE, Nam SJ, Kim DH, Jung HH, Kim JY, Ahn JS, Im YH, Park YH. Oncotarget. 2015 Dec 22;6(41):43731-42.

Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Lee JY, Kim SY, Park C, Kim NK, Jang J, Park K, Yi JH, Hong M, Ahn T, Rath O, Schueler J, Kim ST, Do IG, Lee S, Park SH, Ji YI, Kim D, Park JO, Park YS, Kang WK, Kim KM, Park WY, Lim HY, Lee J. Oncotarget. 2015 Sep 22;6(28):25619-30.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. Lee JY, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ. J Thorac Oncol. 2015 Jun;10(6):903-9

Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. Lee JY, Lim SH, Lee MY, Kim H, Sinn DH, Gwak GY, Choi MS, Lee JH, Jung CW, Jang JH, Kim WS, Kim SJ, Kim K. Liver Int. 2015 Nov;35(11):2363-9.

The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. Lee JY, Hong M, Kim ST, Park SH, Kang WK, Kim KM, Lee J. Sci Rep. 2015 Mar 19;5:9289

Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Lee JY, Lim SH, Kim SJ, Lee GY, Lee JE, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K. Amyloid. 2014 Dec;21(4):261-6.

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Lee JY, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ. Cancer Chemother Pharmacol. 2014 May;73(5):1063-70

The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. Kim HS, Heo JS, Lee J, Lee JY, Lee MY, Lim SH, Lee WY, Kim SH, Park YA, Cho YB, Yun SH, Kim ST, Park JO, Lim HY, Choi YS, Kwon WI, Kim HC, Park YS. BMC Cancer. 2016 Feb 18;16(1):120

Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement. Lee MY, Kim HS, Lee JY, Lim SH, Kang ES, Ko YH, Kim SJ, Kim WS. Int J Hematol. 2015 Oct 22.

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH, Baek CH, Son YI, Jeong HS, Ahn YC, Lee MY, Hong M, Ahn MJ. Cancer Res Treat. 2015 Sep 15.